Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

PREDNISOLONE FOR SYSTEM SUITABILITY CRS (10 MG)

PREDNISOLONE FOR SYSTEM SUITABILITY CRS (10 MG)

50-24-8

DISCOVER
NICERGOLINE IMPURITY D CRS (20 MG)

NICERGOLINE IMPURITY D CRS (20 MG)

20826-04-4

DISCOVER
BUTYL PARAHYDROXYBENZOATE IMPURITY E CRS (15 MG)

BUTYL PARAHYDROXYBENZOATE IMPURITY E CRS (15 MG)

03/02/4247

DISCOVER
GLYCOPYRRONIUM IMPURITY N CRS(10 MG)

GLYCOPYRRONIUM IMPURITY N CRS(10 MG)

NA

DISCOVER
PREDNISOLONE FOR PEAK IDENTIFICATION CRS (10 MG)

PREDNISOLONE FOR PEAK IDENTIFICATION CRS (10 MG)

50-24-8

DISCOVER
BETAXOLOL FOR PEAK IDENTIFICATION CRS (15 MG)

BETAXOLOL FOR PEAK IDENTIFICATION CRS (15 MG)

63659-19-8

DISCOVER
AMPHOTERICIN B FOR MICROBIOLOGICAL ASSAY CRS (100 MG)

AMPHOTERICIN B FOR MICROBIOLOGICAL ASSAY CRS (100 MG)

1397-89-3

DISCOVER
NICERGOLINE FOR PEAK IDENTIFICATION CRS (1 MG)

NICERGOLINE FOR PEAK IDENTIFICATION CRS (1 MG)

27848-84-6

DISCOVER
GENTAMICIN FOR PEAK IDENTIFICATION CRS (10 MG)

GENTAMICIN FOR PEAK IDENTIFICATION CRS (10 MG)

1405-41-0

DISCOVER
ETOPOSIDE FOR SYSTEM SUITABILITY CRS (10 MG)

ETOPOSIDE FOR SYSTEM SUITABILITY CRS (10 MG)

33419-42-0

DISCOVER
TORASEMIDE IMPURITY E CRS (0.0006 MG)

TORASEMIDE IMPURITY E CRS (0.0006 MG)

NA

DISCOVER
CEFPROZIL FOR PEAK IDENTIFICATION CRS (10 MG)

CEFPROZIL FOR PEAK IDENTIFICATION CRS (10 MG)

121123-17-9

DISCOVER